Serono drug draws FDA warning on heart risk

The FDA issued a warning that Serono's multiple sclerosis drug Novantrone raised the risk of heart damage. A boxed warning has been added to the drug's packaging, and the Swiss company has advised patients to be tested for heart disease before dosing. Patients taking Novantrone can experience congestive heart failure during therapy or even years after therapy is completed. The drug was approved by the FDA in 2000. In recent months the agency has raised a number of drug alerts as it responds to criticism that it ignored earlier signs of unsafe drugs.

- read this story from Dow Jones for more on the warning 

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.